Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Celltex Therapeutics Corporation
483
•Celltex Therapeutics Corporation•April 27, 2012

Celltex Therapeutics Corporation – FDA 483, Apr 27, 2012

Record Details

An FDA inspection conducted from April 16 to April 27, 2012, at Celltex Therapeutics Corporation in Sugarland, TX, a biological drug manufacturer, revealed significant deviations from regulatory requirements. The observations primarily concerned the manufacturing of mesenchymal stem cells (MSCs) intended for patient administration. Key violations included a systemic lack of process validation for MSC production, failing to ensure batch uniformity, integrity, and sterility. Specifically, Celltex did not validate critical manufacturing steps, aseptic gowning procedures, or the banking and thawing processes. Sterility test failures were noted without proper investigation or destruction records for affected batches. Environmental monitoring was inadequate, with microbial isolations exceeding specifications and no identification or investigation. Furthermore, the company failed to maintain comprehensive documentation, including batch production and control records, equipment calibration logs, and records for the receipt and disposition of critical supplies and reagents. Many reagents used were labeled "FOR RESEARCH USE ONLY," indicating they were not suitable for human therapeutic use. Quality control unit reviews of manufacturing records were incomplete prior to product release. Equipment like centrifuges was inappropriately operated on the floor, and product labels lacked essential information like sterility status, strength, and biohazard warnings. Basic facility deficiencies included the absence of a hand washing facility in the cleanroom area, posing contamination risks. These observations highlight a need for Celltex Therapeutics Corporation to implement robust corrective and preventive actions to ensure compliance with good manufacturing practices and safeguard product quality and patient safety.

Company
Celltex Therapeutics Corporation
Inspection date
April 27, 2012
Office
Dallas District Office
Person
  • Joel Martinez (Investigator)
View Company Profile

ID · 86c87d39-1d07-4f07-b209-6dae485136d5

Other documents for Celltex Therapeutics Corporation
  • WARNING_LETTER - 2012-04-27April 27, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Celltex Therapeutics Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.